This is a routine annual meeting 8-K with no financial data or material corporate events. No trading action is warranted. Monitor upcoming quarterly filings for pipeline updates and cash runway, which are the primary value drivers for this micro-cap biotech.
Price Chart
Executive Summary
Quoin Pharmaceuticals filed an 8-K reporting results from its 2026 Annual General Meeting. Shareholders approved routine items including director elections, executive compensation on an advisory basis, changes to the 401(k) plan matching contributions, and amendments to the non-employee director compensation program—increasing the annual base retainer to up to $250,000 and the option award range to $20,000–$200,000. The filing contains no financial results, no officer departures, and no material operational or regulatory catalysts, making it a routine governance update with no actionable trading signal.
Key Facts
- Shareholders elected all seven director nominees with strong support (Natalie Leong received the most opposition at ~15% against).
- Advisory vote on named executive officer compensation passed with ~91% of votes cast in favor.
- Non-employee director compensation program amended: annual base retainer increased to up to $250,000; option award range set to $20,000–$200,000, both at Compensation Committee discretion.
- Changes to 401(k) plan matching contributions approved.
- CBIZ CPAs P.C. ratified as independent auditor with ~98% of votes cast in favor.
- No financial results, guidance, or material business developments reported.
Financial Impact
No financial impact disclosed. Director compensation changes are routine and immaterial relative to the company's $9M market cap.
Risk Factors
- No material risks identified from this filing; the company's fundamental risks (cash burn, clinical-stage pipeline, potential dilution) remain unchanged.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-099239 |
| Document: 0001104659-26-099239-index-headers.html | 0001104659-26-099239 |
| Document: 0001104659-26-099239-index.html | 0001104659-26-099239 |
| Document: 0001104659-26-099239.txt | 0001104659-26-099239 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 12, 2026 6d ago | ANALYST-UPGRADE | $4.36 $4.15 | ▼ −4.82% | ▼ −4.80% | $3.90 (−10.55%) |
Sep 2, 2026 6w ago | Insider Cluster | $6.74 $7.87 | ▲ +16.77% | ▲ +15.72% | $3.90 (−42.14%) |
Aug 28, 2026 7w ago | 8-K | $6.12 $6.22 | ▲ +1.63% | ▲ +1.93% | $3.90 (−36.27%) |
Aug 28, 2026 7w ago | Press Release | $6.12 $6.22 | ▼ −1.63% | ▼ −1.93% | $3.90 (+36.27%) |
Aug 28, 2026 7w ago | Press Release | $6.12 $6.22 | ▲ +1.63% | ▲ +1.93% | $3.90 (−36.27%) |
Aug 20, 2026 8w ago | 8-K | $5.57 $5.42 | ▼ −2.69% | ▼ −2.40% | $3.90 (−29.98%) |
Aug 7, 2026 10w ago | Press Release | $4.79 $5.36 | ▲ +11.90% | ▲ +11.93% | $3.90 (−18.58%) |
Jun 23, 2026 16w ago | 8-K | $3.83 $4.20 | ▲ +9.66% | ▲ +9.52% | $3.90 (+1.83%) |
May 7, 2026 23w ago | Press Release | $6.37 $5.93 | ▼ −6.91% | ▼ −7.74% | $3.90 (−38.78%) |
May 5, 2026 23w ago | ANALYST-UPGRADE | $6.31 $6.43 | ▲ +1.90% | ▲ +0.52% | $3.90 (−38.19%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access